ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines.

@article{Stewart2004ISCOMATRIXAA,
  title={ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines.},
  author={Trina J. Stewart and Debbie Drane and Jim Malliaros and Heidi Elmer and Karen M Malcolm and John C Cox and Stirling J Edwards and Ian H Frazer and Germain J. P. Fernando},
  journal={Vaccine},
  year={2004},
  volume={22 27-28},
  pages={3738-43}
}
Human Papillomavirus type 16 (HPV16) E6 and E7 oncoproteins are associated with cervical cancer development and progression and can therefore be used as target antigens for cancer immunotherapy. In this study we evaluated the immunogenicity in mice, of different vaccine formulations using recombinant HPV16 derived E6E7 or E7GST fusion proteins. When co-administered with ISCOMATRIX adjuvant, these E6E7 proteins consistently induced E7 specific CTL, in vivo tumor protection, antibody and DTH… CONTINUE READING